Celecoxib Production Cost Reports

The report provides detailed analysis essential for establishing a celecoxib production plant. It encompasses all critical aspects necessary for celecoxib production, including the cost of celecoxib production, celecoxib plant cost, celecoxib production costs, and the overall celecoxib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a celecoxib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Celecoxib Market Analysis: Demand and Supply Analysis, and Sourcing

Celecoxib is a selective COX-2 inhibitor used to treat pain and inflammation. Chemically it is a diaryl pyrazole with a sulfonamide group and a trifluoromethyl group. It works by blocking the COX-2 enzyme, which lowers pain and inflammation with less stomach injury than older drugs. The drug treats arthritis, acute pain, and menstrual pain, and it helps in a colon-polyp condition. Being an off-patent generic, it holds broad, steady, and global demand. Sold first as Celebrex, it lost patent protection in the mid-2010s and is now widely genericized. Today the molecule is mature, high in volume, and made at large scale.

Buyers are pharmaceutical and generic drug makers, along with API traders and distributors. Demand runs through capsules for arthritis and pain, in a range of strengths. Supply is concentrated in India and China, where large NSAID plants run the bulk of world capacity. A celecoxib demand and supply analysis has to weigh the hydrazine-sulfonamide and diketone cost, the pyrazole synthesis, polymorph and impurity control, and steady pain and arthritis demand. On receipt, buyers check assay by HPLC, related substances, polymorph form, residual solvents, and water content.

Summary of the Product, Grades, and Uses

Celecoxib carries the molecular formula C17H14F3N3O2S and a molar mass of 381.37 g/mol under CAS 169590-42-5. It is a white to off-white crystalline powder that is practically insoluble in water and soluble in methanol and chloroform. The melting point runs around 157 to 159 °C, and it is odorless with a faint taste. Being a neutral sulfonamide pyrazole, it is dosed as the free molecule, not as a salt, in capsules. It shows polymorphism, so the crystal form is controlled for consistent quality. In storage, it holds up well when kept cool, dry, sealed, and away from light.

Celecoxib reaches the market mainly as a single high-purity pharmaceutical grade. Pharmaceutical grade meets USP, European Pharmacopoeia, and BP monographs for capsules, with tight polymorph and impurity control. Indian Pharmacopoeia grade serves the home market under the same tight limits. It ships as a fine crystalline powder of a controlled polymorph to suit capsule blending. Buyers check assay by HPLC, related substances, individual impurities, polymorph form, residual solvents, and microbial limits against the specification.

Across the label, the roles center on pain, inflammation, and arthritis. In arthritis, it treats osteoarthritis and rheumatoid arthritis with less stomach injury than older NSAIDs. In acute care, it treats short-term pain and menstrual pain. In a colon-polyp condition, it helps reduce polyps in familial adenomatous polyposis. The COX-2 selectivity and the gentler stomach profile are its main advantages, though a heart-risk warning shapes use. Across these uses, the value comes from effective pain relief, a gentler stomach profile, low cost, and a long record. Arthritis and pain demand is broad and steady. Its stomach profile drives choice. Such lab work covers pharmacology assays, method development, polymorph checks, and analytical work. Reference and research use is small, mostly analytical and pharmacology work in labs.

Main End-Uses of Celecoxib

The main use of celecoxib is as an oral anti-inflammatory and pain drug, and this covers most demand. In practice, it goes into capsules across a range of strengths for arthritis and pain. Buyers are pharmaceutical and generic formulators who run pain and anti-inflammatory lines. On this outlet, they weigh assay, related substances, polymorph form, and reliable supply. Used as a bulk active, one batch serves a large number of finished doses. On the buyer side, checks cover assay, related substances, polymorph form, and dissolution. For a COX-2 inhibitor API, the sensitive attributes are related substances, polymorph form, individual impurities, and assay.

Arthritis treatment is the largest setting. Capsules treat osteoarthritis and rheumatoid arthritis over the long term, where the gentler stomach profile matters. A large, steady arthritis market drives most of the volume. On uptake, the drivers are efficacy, the stomach profile, cost, and prescriber habit. Here the value comes from effective relief, the stomach profile, low cost, and compendial quality. NSAIDs are a crowded field. The heart-risk warning shapes use. Formulators value polymorph control and a clean impurity profile here, since consistency matters.

Acute pain and specialty use is the second major setting. Capsules treat short-term pain and menstrual pain, and the drug is also used to reduce polyps in a colon condition. Together these outlets keep the volume high. On the specification side, the key attributes are related substances, polymorph form, individual impurities, and assay. Reference and comparator use accounts for the small remainder of demand, covering pharmacology assays, method development, and analytical work in labs.

Celecoxib Market Risks

Celecoxib sits in the generic NSAID market, so its main risks are price pressure and the heart-risk warning rather than demand. Competition is heavy, since many makers produce the same COX-2 inhibitor at low margins. Supply leans on India and China, so any policy shift, energy swing, or plant action there moves the whole market. The boxed cardiovascular warning shapes prescribing, since heart risk has to be weighed against the stomach benefit. Environmental rules on solvents and fluorine chemistry have also tightened, especially in China. On balance, the main pressures are price competition, supply concentration, the safety warning, and tighter rules. Arthritis and pain demand holds up well. Most risk sits on cost and safety.

Celecoxib manufacturing carries its own risks because the pyrazole synthesis and polymorph control both demand tight work. The diketone and the pyrazole ring have to be built cleanly, or related substances and the wrong isomer build up. The ring-forming reaction has to favor the right pyrazole regiochemistry, since a wrong isomer is a specified impurity. Polymorph form has to be controlled, since the wrong crystal form changes dissolution and quality. Related substances and individual impurities are tightly specified, so purification has to be thorough. Most rejected batches trace back to related substances, the regioisomer, polymorph, and assay failures.

Celecoxib Production Process and Main Cost Drivers

The celecoxib production process runs the full value chain, from the diketone and hydrazine-sulfonamide receipt through condensation, pyrazole formation, purification, polymorph control, crystallization, and drying.

1. By Pyrazole Ring Formation from a Trifluoromethyl Diketone and a Hydrazine Sulfonamide: The main inputs are 4,4,4-trifluoro-1-(4-methylphenyl)butane-1,3-dione, 4-hydrazinylbenzenesulfonamide, an acid catalyst, organic solvents & purified water.

Celecoxib production opens with receipt and QC of the trifluoromethyl diketone and the hydrazine-sulfonamide. To start, the diketone is prepared or received, ready to react with the hydrazine-sulfonamide. This diketone carries the trifluoromethyl and tolyl groups that end up in the molecule. The intermediate is checked before the ring step, since impurities carry forward otherwise.

Next, the diketone is condensed with 4-hydrazinylbenzenesulfonamide under an acid catalyst, which closes the pyrazole ring and builds celecoxib. The crude is worked up, then purified and crystallized under conditions that fix the correct polymorph. The product is filtered, dried & milled to specification under impurity and polymorph control. Across the process, the critical controls are ring regiochemistry, polymorph form, related substances, and color. The right pyrazole isomer has to dominate, since the wrong one is an impurity. QC covers assay, related substances, individual impurities, polymorph form, residual solvents, and water content. The main levers on cost are the diketone and hydrazine-sulfonamide price, ring yield, regiochemistry & purification recovery.

Main Factors Affecting Celecoxib Production Cost

Celecoxib production cost is shaped mainly by the two building blocks and the yield of the pyrazole ring step. The trifluoromethyl diketone and the hydrazine-sulfonamide are the costliest inputs, since they are specialty fine chemicals. Because the route runs several steps to the diketone and the ring, yield losses compound and shape the cost per kilogram. On the process side, the acid catalyst, solvents, and utilities are steady, ongoing costs. Energy for the reactions, purification & drying is a real utility item. On the testing side, HPLC for related substances and the regioisomer, polymorph & residual-solvent tests make up a large share of the QC spend. On the running side, the biggest cost lines are the intermediates, energy, solvents, and testing. Feedstock is the main driver. Yield losses come next.

Unit cost also moves with regiochemistry and polymorph control. A batch with a high wrong-isomer share or the wrong crystal form takes extra work and loses yield. Because the pyrazole step can give two isomers, controlling regiochemistry is central to a clean, high-yield process. Fluorine chemistry and solvent handling raise effluent and safety costs that have to be managed. GMP documentation, pharmacopoeia compliance & regulatory upkeep are carried as fixed overhead. The synthesis train, purification & analytical burden all carry heavy fixed overhead, so a plant running below capacity spreads that overhead over fewer kilograms and lands at a higher unit cost.

Raw Materials for Celecoxib Production Plant and its Procurement

Raw material sourcing for celecoxib centers on the trifluoromethyl diketone and the hydrazine-sulfonamide. The diketone is the primary specialty feedstock, made through fluorine and ketone chemistry at fine-chemical plants. It ships from a limited set of makers, mostly in Asia where NSAID intermediate capacity is concentrated today. Alongside it, the 4-hydrazinylbenzenesulfonamide, acid catalyst, organic solvents, and purified water complete the input streams.

Cheaper diketone is not always the cheapest route to finished celecoxib. A feed with related impurities carries side products into the pyrazole step. Feedstock quality also shapes the related-substance and isomer profile, which is critical for a pharmaceutical grade. Taken together, diketone purity, hydrazine-sulfonamide quality, ring yield, regiochemistry, and purification recovery drive most of the variable cost per kilogram.

Such sensitivities shape how a celecoxib plant buys and qualifies its inputs. Contracts specify intermediate purity, related impurities, isomer markers & moisture, and every incoming lot is quarantined until QC release. Vendor qualification runs through supplier audits, review of the synthesis chain & lot-to-lot monitoring. On the incoming side, checks cover assay, related impurities, isomer content, and moisture. Long-term agreements with two intermediate suppliers help steady cost, timing, quality, and supply. Siting the plant inside an NSAID cluster with intermediate supply adds real freight, feedstock & compliance advantages, since the building blocks are made nearby.

Sustainability and Regulatory Requirements

Celecoxib manufacture raises environmental concerns that center on solvent use, fluorine chemistry & organic effluent. Standard controls rely on solvent recovery, chemical effluent treatment, control of fluoride and salt streams & control of organic waste before discharge. Solvent use is the sharpest concern, since the route runs several organic solvents, so recovery and containment matter. Solvent recovery and energy integration cut both cost and footprint. On the sustainability side, the themes are solvent recovery, effluent treatment, fluoride control, and energy use. Tighter environmental rules in China have already closed weaker plants and lifted compliance spending across the industry. Solvent and effluent control is the sharpest issue. Full documentation is expected.

Regulatory obligations for celecoxib follow from its use as a widely prescribed NSAID. In the US, the API sits under FDA cGMP per 21 CFR 210/211 and the USP monograph, and the label carries a boxed cardiovascular warning. In Europe, an EU GMP site with a Certificate of Suitability to the European Pharmacopoeia is needed for regulated supply. ICH Q7 for active ingredients applies, along with BP, EP & USP limits on related substances and polymorph. Indian grades follow their own pharmacopoeia limits. On the compliance side, the duties span cGMP, the compendial monograph, impurity and polymorph limits, and effluent standards. Sites usually carry ISO 14001 and ISO 45001 certification, and batch release rests on assay, related substances, polymorph form & microbial limits.

CAPEX and OPEX for a Celecoxib Production Plant

A celecoxib plant is a multi-step synthesis and purification facility built around pyrazole chemistry. Plant investment starts with intermediate and reagent storage, a diketone-preparation or receipt section, and a pyrazole-ring reactor. From there come a work-up and neutralization section, a purification and polymorph-control step, and a crystallization, drying & milling suite. Utilities cover chilled brine, steam, purified water, solvent recovery & an effluent treatment plant. On the QC side, a laboratory block houses HPLC, related-substance and polymorph testing, residual-solvent & water analysis. Civil works provide contained reactor bays, a solvent store, a drying and packing area & a controlled-access warehouse. On the capital side, the big blocks are the synthesis reactors, the purification train, the effluent plant, and the drying suite. Polymorph-controlled crystallization runs through finishing, since the crystal form matters.

Celecoxib operating cost comes from the same inputs and control points that shape the process. The variable side is led by the diketone, the hydrazine-sulfonamide, the acid catalyst & solvents, alongside energy, labor, testing, effluent treatment, packaging & freight. Cost per kilogram then comes down to ring yield, regiochemistry & purification recovery. The celecoxib plant setup cost depends on capacity, synthesis and purification scale, polymorph-control scope & grade range. Taken together, intermediate price, ring yield, purification recovery, energy use & compliance determine the running cost.

Plant Location and Investment Factors

A workable celecoxib site sits inside an NSAID cluster with intermediate supply and strong effluent infrastructure. Access to trained synthesis and QC staff is essential. India's fine-chemical hubs pair diketone and sulfonamide supply with NSAID chemistry and formulation capacity. China adds intermediate and API capacity with a low cost base and large chemical infrastructure. Both regions offer deep supplier networks, scale & established NSAID supply chains. The site also needs solvent handling, fluorine-chemistry capability & a full effluent treatment plant for chemical waste.

For a celecoxib plant, the main investment decision is whether to make the trifluoromethyl diketone in-house or buy it and run only the ring step and finishing. Buying the diketone lowers capital but leaves the biggest cost exposed to the intermediate market. Making it in-house raises CAPEX but secures supply and captures more value. Whether to serve regulated markets or price-driven generic markets is the other decision, since regulated grades need tighter polymorph and impurity control. Plant scale has to match steady but price-sensitive demand, so the project rests on cost leadership and reliable quality. For a maker targeting regulated markets, polymorph and impurity control & compendial quality matter most. Regulated grades pay better. Generic grades move volume.

Major Celecoxib Producing Regions

India and China are the core production regions for celecoxib today. India runs most of the world's celecoxib API and finished-dose capacity, backed by large fine-chemical clusters. Regional strength rests on cheap intermediates, scale, integration, and formulation depth. China adds intermediate and API capacity with a low cost base and large chemical infrastructure. Europe holds limited but high-value capacity through specialty API makers for regulated markets. The United States relies mainly on imported API, with finished-dose work at home. Across the map, the value chain spans the trifluoromethyl diketone, the hydrazine-sulfonamide, pyrazole formation, and finishing. A new plant would most likely start in an Indian or Chinese NSAID cluster with existing intermediate and effluent capacity.

Key Celecoxib Producers

Dr. Reddy's Laboratories

• Ranks among India's leading API and formulation makers, active in celecoxib.
• Produces celecoxib API and finished doses for regulated and export markets.
• Competes on integration, scale & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Aurobindo Pharma

• Manufactures a broad API and finished-dose range, including celecoxib, from India.
• Runs multi-step synthesis and formulation for regulated and emerging markets.
• Competes on scale, backward integration & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Strides Pharma Science

• Produces celecoxib and other APIs and finished doses from its base in India.
• Runs synthesis and formulation for regulated and emerging markets.
• Competes on formulation depth, capacity & regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Zhejiang Hisun Pharmaceutical

• Operates as a major Chinese API maker with large-scale capacity, including celecoxib.
• Produces celecoxib and other APIs from an integrated chemical base.
• Competes on a low Chinese cost base, scale & a broad API portfolio.
• Regulatory work covers Chinese and export standards for APIs.

Tianjin Tianyao Pharmaceutical

• Runs API and fine-chemical capacity from its base in China, with celecoxib in its range.
• Produces celecoxib and other APIs for domestic and export markets.
• Competes on scale, integration & a low cost base.
• Regulatory work covers Chinese and export standards for APIs.

Gonane Pharma

• Specializes in NSAID and other APIs, including celecoxib, from India.
• Runs synthesis and export supply for regulated and emerging markets.
• Competes on NSAID focus, capacity & a competitive cost base.
• Regulatory work covers Indian registration and export documentation.